Aflibercept Biosimilar is a fusion protein commercialized by Sandoz Group, with a leading Phase III program in Wet (Neovascular / Exudative) Macular Degeneration. According to Globaldata, it is involved in 3 clinical trials, which were completed. GlobalData uses proprietary data and analytics to provide a complete picture of Aflibercept Biosimilar’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Aflibercept Biosimilar is expected to reach an annual total of $189 mn by 2039 globally based off GlobalData’s Revenue Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Aflibercept Biosimilar Overview
Aflibercept biosimilar (SOK583A1) is under development for the treatment of wet age-related macular degeneration. It is administered through intravitreal route as solution. The drug candidate acts by targeting placenta growth factor (PGF) and vascular endothelial growth factor A.
Sandoz Group Overview
Sandoz Group develops, manufactures and distributes generics and biosimilar medical products used for the treatment of various life threatening diseases. The company is headquartered in Zug City, Zug, Switzerland.
The company reported revenues of (US Dollars) US$9,306 million for the fiscal year ended December 2022 (FY2022), a decrease of 3.8% over FY2021. In FY2022, the company’s operating margin was 13.3%, compared to an operating margin of 14.4% in FY2021. In FY2022, the company recorded a net margin of 9.1%, compared to a net margin of 9.4% in FY2021.
For a complete picture of Aflibercept Biosimilar’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.